The extent of life expectancy varies depending on the species, as well as among members of the same species to a certain extent. To understand the differences in life expectancy, as well as the factors that define one’s longevity, a closer look at the current aging situation will be required. Among the most notable theories explaining life expectancy in humans, one should mention the programmed theories, which suggest that longevity rates are defined in people’s nature by their genes (Sahu et al., 2020). Additionally, the theories viewing the process of aging s tee direct outcome of the organism, and damage over time should be listed as possible explanations of the process. Understanding the specified theories has become critical since the percentage of late adults has increased globally (Uzuegbunam et al., 2020). Furthermore, the specified population is likely to face several health issues, including the thickness of blood vessels and the resulting threat of cardiovascular disease (*Sahu et al., 2020). Therefore, further focus on the issue of aging adults and their needs must be prioritized.
Though programmed theories and damaged, or error, theories, seek to explain the same phenomenon, there is a notable difference between them. Programmed theories suggest that specific life expectancy is coded into one’s genes a den, therefore, cannot be expanded. In turn, the damaged theories seek to explain the process of aging as the outcome of cells being corrupted and damaged (*Sahu et al., 2020). Therefore, applying the damage/error theory to the issue of growing p is likely to lead to perceiving p-puberty and the changes that it is going to entail in children’s bodies as a direct threat to young leaders’ mental and psychological well-been. Overall, the existing theoretical frameworks cover the key points, yet a more insightful premise could be considered an option.
Sahu, A. K., Padhy, R. K., & Dhir, A. (2020). Envisioning the future of behavioral decision-making: A systematic literature review of behavioral reasoning theory. Australasian Marketing Journal (AMJ), 28(4), 145-159.
Uzuegbunam, B. C., Librizzi, D., & Hooshyar Yousefi, B. (2020). PET radiopharmaceuticals for Alzheimer’s disease and Parkinson’s disease diagnosis, the current and future landscape. Molecules, 25(4), 977.